Eli Lilly's performance in the biopharmaceutical sector reflects its strong market position, despite facing challenges. The ...

U.S. stock futures ticked higher on Wednesday as investors geared up for quarterly earnings from artificial intelligence-darling Nvidia (more below). In individual stocks, Eli Lilly (NYSE:LLY) shares ...

Viking Therapeutics (NASDAQ: VKTX) soared into the spotlight about a year ago when it delivered promising data on a drug ...

Patrik Jonsson is the president of Eli Lilly & Co.'s cardiometabolic health unit. "Eli Lilly to Offer Higher Doses of Obesity Drug Zepbound at Discounted Prices," at 9:48 a.m. ET, incorrectly said his ...

U.S. stocks struggled today, with the S&P 500 and the Nasdaq touching one-month lows as a dour consumer confidence report put ...

Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.

Legislators may launch a study of how weight loss drugs might reduce costs in the Iowa Medicaid program. Jeffrey Boeyink is a ...

Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for ...

Hugely popular weight loss drugs known as GLP-1's are finally getting cheaper, well at least one is, and that's the case with ...

Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...

Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...

The pharma giant will now offer 7.5mg and 10mg dosages of Zepbound, as well as lower rates for its 2.5mg and 5mg vials.